Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020
Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020
SUMMARY
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 40 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 7, 1, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Metastatic Melanoma, Bladder Cancer, Glioblastoma Multiforme (GBM), Colorectal Cancer, Lung Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Alopecia, Breast Cancer, Cervical Cancer, Colon Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.
The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 40 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 7, 1, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Metastatic Melanoma, Bladder Cancer, Glioblastoma Multiforme (GBM), Colorectal Cancer, Lung Cancer, Recurrent Glioblastoma Multiforme (GBM), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Alopecia, Breast Cancer, Cervical Cancer, Colon Cancer, Colon Carcinoma, Endometrial Cancer, Ependymoma, Gastric Cancer, Glioma, Gliosarcoma, Head And Neck Cancer, Hematological Tumor, High-Grade Glioma, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medulloblastoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ureter Cancer and Urethral Cancer.
The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
- The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
IO Biotech ApS
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Nammi Therapeutics Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Orpheris Inc
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
SignalRx Pharmaceuticals Inc
Suzhou Kintor Pharmaceutical Inc
Syntekabio Inc
Tara Immuno-Oncology Therapeutics LLC
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
(IO-102 + IO-103) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
IO Biotech ApS
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Nammi Therapeutics Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Orpheris Inc
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
SignalRx Pharmaceuticals Inc
Suzhou Kintor Pharmaceutical Inc
Syntekabio Inc
Tara Immuno-Oncology Therapeutics LLC
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
(IO-102 + IO-103) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by BeiGene Ltd, H1 2020
Pipeline by BirchBioMed Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CanBas Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Emcure Pharmaceuticals Ltd, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by IO Biotech ApS, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Kyowa Kirin Co Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Nammi Therapeutics Inc, H1 2020
Pipeline by Netherlands Translational Research Center BV, H1 2020
Pipeline by NewLink Genetics Corp, H1 2020
Pipeline by Orpheris Inc, H1 2020
Pipeline by Phenex Pharmaceuticals AG, H1 2020
Pipeline by Regen BioPharma Inc, H1 2020
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020
Pipeline by Syntekabio Inc, H1 2020
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by BeiGene Ltd, H1 2020
Pipeline by BirchBioMed Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CanBas Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Emcure Pharmaceuticals Ltd, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by IO Biotech ApS, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Kyowa Kirin Co Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Nammi Therapeutics Inc, H1 2020
Pipeline by Netherlands Translational Research Center BV, H1 2020
Pipeline by NewLink Genetics Corp, H1 2020
Pipeline by Orpheris Inc, H1 2020
Pipeline by Phenex Pharmaceuticals AG, H1 2020
Pipeline by Regen BioPharma Inc, H1 2020
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020
Pipeline by Syntekabio Inc, H1 2020
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
IO Biotech ApS
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Nammi Therapeutics Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Orpheris Inc
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
SignalRx Pharmaceuticals Inc
Suzhou Kintor Pharmaceutical Inc
Syntekabio Inc
Tara Immuno-Oncology Therapeutics LLC
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
BeiGene Ltd
BirchBioMed Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
Eli Lilly and Co
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
IO Biotech ApS
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Nammi Therapeutics Inc
Netherlands Translational Research Center BV
NewLink Genetics Corp
Orpheris Inc
Phenex Pharmaceuticals AG
Regen BioPharma Inc
Secarna Pharmaceuticals GmbH & Co. KG
Shanghai De Novo Pharmatech Co Ltd
SignalRx Pharmaceuticals Inc
Suzhou Kintor Pharmaceutical Inc
Syntekabio Inc
Tara Immuno-Oncology Therapeutics LLC
